FRIEL ROBERT F

SEC source: 0001524472-26-000082 · form4.xml · nonDerivative · entry 1

FRIEL ROBERT F · CIK 0001224110 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 38,706

F1 · shares: Reflects an award of restricted stock units pursuant to the Xylem 2011 Omnibus Incentive Plan (Amended and Restated February 24, 2016) that are scheduled to vest in full on the trading day prior to the 2027 Annual Meeting of Shareholders. The Reporting Person has elected to defer the settlement of the RSU Award until Separation from Service.

F2 · balance_after: Includes additional shares due to dividend reinvestment.

SEC source: 0000105770-26-000059 · form4.xml · nonDerivative · entry 1

FRIEL ROBERT F · CIK 0001224110 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,512.97

F1 · shares: These shares of restricted stock units will vest in full on the date of the next annual shareholder meeting and will be distributable under the terms of the Deferred Compensation Plan for Outside Directors.

SEC source: 0001562180-25-003810 · primarydocument.xml · nonDerivative · entry 1

FRIEL ROBERT F · CIK 0001224110 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 36,031

F1 · shares: Reflects an award of restricted stock units pursuant to the Xylem 2011 Omnibus Incentive Plan (Amended and Restated February 24, 2016) that are scheduled to vest in full on the trading day prior to the 2026 Annual Meeting of Shareholders. The Reporting Person has elected to defer the settlement of the RSU Award until Separation from Service.

F2 · balance_after: Includes additional shares due to dividend reinvestment.

SEC source: 0001127602-25-013716 · form4.xml · nonDerivative · entry 1

FRIEL ROBERT F · CIK 0001224110 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,681.98

F1 · shares: These shares of restricted stock units will vest in full on the date of the next annual shareholder meeting and will be distributable under the terms of the Deferred Compensation Plan for Outside Directors.

SEC source: 0001562180-24-004225 · primarydocument.xml · nonDerivative · entry 1

FRIEL ROBERT F · CIK 0001224110 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 33,926

F1 · shares: Reflects an award of restricted stock units pursuant to the Xylem 2011 Omnibus Incentive Plan (Amended and Restated February 24, 2016) that are scheduled to vest in full on the trading day prior to the 2025 Annual Meeting of Shareholders. The Reporting Person has elected to defer the settlement of the RSU Award until Separation from Service.

F2 · balance_after: Includes additional shares due to dividend reinvestment.

SEC source: 0001127602-24-013402 · form4.xml · nonDerivative · entry 1

FRIEL ROBERT F · CIK 0001224110 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,610.98

F1 · shares: These shares of restricted stock units will vest in full on the date of the next annual shareholder meeting and will be distributable under the terms of the Deferred Compensation Plan for Outside Directors.

SEC source: 0001209191-23-048181 · doc4.xml · derivative · entry 10

FRIEL ROBERT F · CIK 0001224110 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 4,816 shares

Expires not disclosed

F1 · derivative.exercise_price: Represented a contingent right to receive one share of the Issuer's common stock upon vesting.

F2 · derivative.exercise_date: Pursuant to the Agreement and Plan of Merger, dated as of February 8, 2023 (the "Merger Agreement"), by and among the Issuer, Globus Medical, Inc. ("Globus") and Zebra Merger Sub, Inc. ("Merger Sub"), Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Globus. At the effective time of the merger, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive 0.75 shares of Class A common stock of Globus, par value $0.001 per share, and cash in lieu of fractional shares, in respect of each share of Issuer common stock underlying such award.

F2 · derivative.expiration_date: Pursuant to the Agreement and Plan of Merger, dated as of February 8, 2023 (the "Merger Agreement"), by and among the Issuer, Globus Medical, Inc. ("Globus") and Zebra Merger Sub, Inc. ("Merger Sub"), Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Globus. At the effective time of the merger, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive 0.75 shares of Class A common stock of Globus, par value $0.001 per share, and cash in lieu of fractional shares, in respect of each share of Issuer common stock underlying such award.

SEC source: 0001209191-23-048181 · doc4.xml · derivative · entry 9

FRIEL ROBERT F · CIK 0001224110 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 3,788 shares

Expires not disclosed

F1 · derivative.exercise_price: Represented a contingent right to receive one share of the Issuer's common stock upon vesting.

F2 · derivative.exercise_date: Pursuant to the Agreement and Plan of Merger, dated as of February 8, 2023 (the "Merger Agreement"), by and among the Issuer, Globus Medical, Inc. ("Globus") and Zebra Merger Sub, Inc. ("Merger Sub"), Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Globus. At the effective time of the merger, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive 0.75 shares of Class A common stock of Globus, par value $0.001 per share, and cash in lieu of fractional shares, in respect of each share of Issuer common stock underlying such award.

F2 · derivative.expiration_date: Pursuant to the Agreement and Plan of Merger, dated as of February 8, 2023 (the "Merger Agreement"), by and among the Issuer, Globus Medical, Inc. ("Globus") and Zebra Merger Sub, Inc. ("Merger Sub"), Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Globus. At the effective time of the merger, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive 0.75 shares of Class A common stock of Globus, par value $0.001 per share, and cash in lieu of fractional shares, in respect of each share of Issuer common stock underlying such award.

SEC source: 0001209191-23-048181 · doc4.xml · derivative · entry 8

FRIEL ROBERT F · CIK 0001224110 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 2,702 shares

Expires not disclosed

F1 · derivative.exercise_price: Represented a contingent right to receive one share of the Issuer's common stock upon vesting.

F2 · derivative.exercise_date: Pursuant to the Agreement and Plan of Merger, dated as of February 8, 2023 (the "Merger Agreement"), by and among the Issuer, Globus Medical, Inc. ("Globus") and Zebra Merger Sub, Inc. ("Merger Sub"), Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Globus. At the effective time of the merger, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive 0.75 shares of Class A common stock of Globus, par value $0.001 per share, and cash in lieu of fractional shares, in respect of each share of Issuer common stock underlying such award.

F2 · derivative.expiration_date: Pursuant to the Agreement and Plan of Merger, dated as of February 8, 2023 (the "Merger Agreement"), by and among the Issuer, Globus Medical, Inc. ("Globus") and Zebra Merger Sub, Inc. ("Merger Sub"), Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Globus. At the effective time of the merger, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive 0.75 shares of Class A common stock of Globus, par value $0.001 per share, and cash in lieu of fractional shares, in respect of each share of Issuer common stock underlying such award.

SEC source: 0001209191-23-048181 · doc4.xml · derivative · entry 7

FRIEL ROBERT F · CIK 0001224110 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 3,095 shares

Expires not disclosed

F1 · derivative.exercise_price: Represented a contingent right to receive one share of the Issuer's common stock upon vesting.

F2 · derivative.exercise_date: Pursuant to the Agreement and Plan of Merger, dated as of February 8, 2023 (the "Merger Agreement"), by and among the Issuer, Globus Medical, Inc. ("Globus") and Zebra Merger Sub, Inc. ("Merger Sub"), Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Globus. At the effective time of the merger, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive 0.75 shares of Class A common stock of Globus, par value $0.001 per share, and cash in lieu of fractional shares, in respect of each share of Issuer common stock underlying such award.

F2 · derivative.expiration_date: Pursuant to the Agreement and Plan of Merger, dated as of February 8, 2023 (the "Merger Agreement"), by and among the Issuer, Globus Medical, Inc. ("Globus") and Zebra Merger Sub, Inc. ("Merger Sub"), Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Globus. At the effective time of the merger, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive 0.75 shares of Class A common stock of Globus, par value $0.001 per share, and cash in lieu of fractional shares, in respect of each share of Issuer common stock underlying such award.

SEC source: 0001209191-23-048181 · doc4.xml · derivative · entry 6

FRIEL ROBERT F · CIK 0001224110 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 2,577 shares

Expires not disclosed

F1 · derivative.exercise_price: Represented a contingent right to receive one share of the Issuer's common stock upon vesting.

F2 · derivative.exercise_date: Pursuant to the Agreement and Plan of Merger, dated as of February 8, 2023 (the "Merger Agreement"), by and among the Issuer, Globus Medical, Inc. ("Globus") and Zebra Merger Sub, Inc. ("Merger Sub"), Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Globus. At the effective time of the merger, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive 0.75 shares of Class A common stock of Globus, par value $0.001 per share, and cash in lieu of fractional shares, in respect of each share of Issuer common stock underlying such award.

F2 · derivative.expiration_date: Pursuant to the Agreement and Plan of Merger, dated as of February 8, 2023 (the "Merger Agreement"), by and among the Issuer, Globus Medical, Inc. ("Globus") and Zebra Merger Sub, Inc. ("Merger Sub"), Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Globus. At the effective time of the merger, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive 0.75 shares of Class A common stock of Globus, par value $0.001 per share, and cash in lieu of fractional shares, in respect of each share of Issuer common stock underlying such award.

SEC source: 0001209191-23-048181 · doc4.xml · derivative · entry 5

FRIEL ROBERT F · CIK 0001224110 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 3,230 shares

Expires not disclosed

F1 · derivative.exercise_price: Represented a contingent right to receive one share of the Issuer's common stock upon vesting.

F2 · derivative.exercise_date: Pursuant to the Agreement and Plan of Merger, dated as of February 8, 2023 (the "Merger Agreement"), by and among the Issuer, Globus Medical, Inc. ("Globus") and Zebra Merger Sub, Inc. ("Merger Sub"), Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Globus. At the effective time of the merger, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive 0.75 shares of Class A common stock of Globus, par value $0.001 per share, and cash in lieu of fractional shares, in respect of each share of Issuer common stock underlying such award.

F2 · derivative.expiration_date: Pursuant to the Agreement and Plan of Merger, dated as of February 8, 2023 (the "Merger Agreement"), by and among the Issuer, Globus Medical, Inc. ("Globus") and Zebra Merger Sub, Inc. ("Merger Sub"), Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Globus. At the effective time of the merger, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive 0.75 shares of Class A common stock of Globus, par value $0.001 per share, and cash in lieu of fractional shares, in respect of each share of Issuer common stock underlying such award.

SEC source: 0001209191-23-048181 · doc4.xml · derivative · entry 4

FRIEL ROBERT F · CIK 0001224110 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 2,130 shares

Expires not disclosed

F1 · derivative.exercise_price: Represented a contingent right to receive one share of the Issuer's common stock upon vesting.

F2 · derivative.exercise_date: Pursuant to the Agreement and Plan of Merger, dated as of February 8, 2023 (the "Merger Agreement"), by and among the Issuer, Globus Medical, Inc. ("Globus") and Zebra Merger Sub, Inc. ("Merger Sub"), Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Globus. At the effective time of the merger, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive 0.75 shares of Class A common stock of Globus, par value $0.001 per share, and cash in lieu of fractional shares, in respect of each share of Issuer common stock underlying such award.

F2 · derivative.expiration_date: Pursuant to the Agreement and Plan of Merger, dated as of February 8, 2023 (the "Merger Agreement"), by and among the Issuer, Globus Medical, Inc. ("Globus") and Zebra Merger Sub, Inc. ("Merger Sub"), Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Globus. At the effective time of the merger, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive 0.75 shares of Class A common stock of Globus, par value $0.001 per share, and cash in lieu of fractional shares, in respect of each share of Issuer common stock underlying such award.

SEC source: 0001209191-23-048181 · doc4.xml · derivative · entry 3

FRIEL ROBERT F · CIK 0001224110 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 2,822 shares

Expires not disclosed

F1 · derivative.exercise_price: Represented a contingent right to receive one share of the Issuer's common stock upon vesting.

F2 · derivative.exercise_date: Pursuant to the Agreement and Plan of Merger, dated as of February 8, 2023 (the "Merger Agreement"), by and among the Issuer, Globus Medical, Inc. ("Globus") and Zebra Merger Sub, Inc. ("Merger Sub"), Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Globus. At the effective time of the merger, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive 0.75 shares of Class A common stock of Globus, par value $0.001 per share, and cash in lieu of fractional shares, in respect of each share of Issuer common stock underlying such award.

F2 · derivative.expiration_date: Pursuant to the Agreement and Plan of Merger, dated as of February 8, 2023 (the "Merger Agreement"), by and among the Issuer, Globus Medical, Inc. ("Globus") and Zebra Merger Sub, Inc. ("Merger Sub"), Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Globus. At the effective time of the merger, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive 0.75 shares of Class A common stock of Globus, par value $0.001 per share, and cash in lieu of fractional shares, in respect of each share of Issuer common stock underlying such award.

SEC source: 0001209191-23-048181 · doc4.xml · derivative · entry 2

FRIEL ROBERT F · CIK 0001224110 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 850 shares

Expires not disclosed

F1 · derivative.exercise_price: Represented a contingent right to receive one share of the Issuer's common stock upon vesting.

F2 · derivative.exercise_date: Pursuant to the Agreement and Plan of Merger, dated as of February 8, 2023 (the "Merger Agreement"), by and among the Issuer, Globus Medical, Inc. ("Globus") and Zebra Merger Sub, Inc. ("Merger Sub"), Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Globus. At the effective time of the merger, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive 0.75 shares of Class A common stock of Globus, par value $0.001 per share, and cash in lieu of fractional shares, in respect of each share of Issuer common stock underlying such award.

F2 · derivative.expiration_date: Pursuant to the Agreement and Plan of Merger, dated as of February 8, 2023 (the "Merger Agreement"), by and among the Issuer, Globus Medical, Inc. ("Globus") and Zebra Merger Sub, Inc. ("Merger Sub"), Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Globus. At the effective time of the merger, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive 0.75 shares of Class A common stock of Globus, par value $0.001 per share, and cash in lieu of fractional shares, in respect of each share of Issuer common stock underlying such award.

SEC source: 0001209191-23-048181 · doc4.xml · derivative · entry 1

FRIEL ROBERT F · CIK 0001224110 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 5,113 shares

Expires not disclosed

F1 · derivative.exercise_price: Represented a contingent right to receive one share of the Issuer's common stock upon vesting.

F2 · derivative.exercise_date: Pursuant to the Agreement and Plan of Merger, dated as of February 8, 2023 (the "Merger Agreement"), by and among the Issuer, Globus Medical, Inc. ("Globus") and Zebra Merger Sub, Inc. ("Merger Sub"), Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Globus. At the effective time of the merger, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive 0.75 shares of Class A common stock of Globus, par value $0.001 per share, and cash in lieu of fractional shares, in respect of each share of Issuer common stock underlying such award.

F2 · derivative.expiration_date: Pursuant to the Agreement and Plan of Merger, dated as of February 8, 2023 (the "Merger Agreement"), by and among the Issuer, Globus Medical, Inc. ("Globus") and Zebra Merger Sub, Inc. ("Merger Sub"), Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Globus. At the effective time of the merger, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive 0.75 shares of Class A common stock of Globus, par value $0.001 per share, and cash in lieu of fractional shares, in respect of each share of Issuer common stock underlying such award.

SEC source: 0001209191-23-036447 · doc4.xml · derivative · entry 1

FRIEL ROBERT F · CIK 0001224110 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,816

Underlying: Common Stock · 4,816 shares

Expires not disclosed

F1 · security: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's common stock upon vesting.

F2 · derivative.exercise_date: Award of RSUs pursuant to Issuer's Board of Director's compensation policies granted under Issuer's 2014 Equity Incentive Plan. The grant will vest in full on the first to occur of (1) Issuer's 2024 Annual Meeting of Stockholders, or (2) the one-year anniversary of the date of grant. Settlement of this award has been deferred until the Reporting Person's separation from service with the Issuer's Board of Directors.

F3 · derivative.exercise_date: On February 8, 2023, Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Globus Medical, Inc. ("Globus Medical") and Zebra Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Globus Medical. The Merger Agreement provides, among other things, that subject to the satisfaction or waiver of the conditions set forth therein, Merger Sub will merge with and into Issuer (the "Merger"), with Issuer surviving the Merger as a wholly owned subsidiary of Globus Medical. Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each RSU outstanding immediately prior to the Effective Time held by the Reporting Person will fully vest and be cancelled and converted automatically into the right to receive (without interest) 0.75 fully paid and non-assessable shares of Class A common stock of Globus Medical (and cash in lieu of any fractional shares) in respect of each share of Issuer's common stock underlying such RSU.

F2 · derivative.expiration_date: Award of RSUs pursuant to Issuer's Board of Director's compensation policies granted under Issuer's 2014 Equity Incentive Plan. The grant will vest in full on the first to occur of (1) Issuer's 2024 Annual Meeting of Stockholders, or (2) the one-year anniversary of the date of grant. Settlement of this award has been deferred until the Reporting Person's separation from service with the Issuer's Board of Directors.

F3 · derivative.expiration_date: On February 8, 2023, Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Globus Medical, Inc. ("Globus Medical") and Zebra Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Globus Medical. The Merger Agreement provides, among other things, that subject to the satisfaction or waiver of the conditions set forth therein, Merger Sub will merge with and into Issuer (the "Merger"), with Issuer surviving the Merger as a wholly owned subsidiary of Globus Medical. Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each RSU outstanding immediately prior to the Effective Time held by the Reporting Person will fully vest and be cancelled and converted automatically into the right to receive (without interest) 0.75 fully paid and non-assessable shares of Class A common stock of Globus Medical (and cash in lieu of any fractional shares) in respect of each share of Issuer's common stock underlying such RSU.

SEC source: 0001562180-23-004394 · primarydocument.xml · nonDerivative · entry 1

FRIEL ROBERT F · CIK 0001224110 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 32,017

F1 · shares: Reflects an award of restricted stock units pursuant to the Xylem 2011 Omnibus Incentive Plan (Amended and Restated February 24, 2016) that are scheduled to vest in full on the trading day prior to the 2024 Annual Meeting of Shareholders. The Reporting Person has elected to defer the settlement of the RSU Award until Separation from Service

F2 · balance_after: Includes additional shares due to dividend reinvestment.

SEC source: 0001562180-23-003698 · primarydocument.xml · nonDerivative · entry 1

FRIEL ROBERT F · CIK 0001224110 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,046.98

F1 · price: These shares of restricted stock units will vest in full on the first anniversary of the date of the grant and will be distributable under the terms of the Deferred Compensation Plan for Outside Directors.

SEC source: 0001562180-22-004433 · primarydocument.xml · nonDerivative · entry 1

FRIEL ROBERT F · CIK 0001224110 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,430.98

F1 · price: These shares of restricted stock units will vest in full on the first anniversary of the date of grant and will be distributable under the terms of the Deferred Compensation Plan for Outside Directors.

SEC source: 0001209191-22-029335 · doc4.xml · nonDerivative · entry 1

FRIEL ROBERT F · CIK 0001224110 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 29,538

F1 · shares: Reflects the award of restricted stock units. The Reporting Person elected to defer the vesting of the RSU Award until Separation from Service.

F2 · balance_after: Amount shown reflects additional shares acquired via a dividend reinvestment plan or DRIP.

SEC source: 0001209191-22-028935 · doc4.xml · derivative · entry 1

FRIEL ROBERT F · CIK 0001224110 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,788

Underlying: Common Stock · 3,788 shares

Expires not disclosed

F1 · security: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's common stock upon vesting.

F2 · derivative.exercise_date: Award of RSUs pursuant to Issuer's Board of Director's compensation policies granted under Issuer's 2014 Equity Incentive Plan. The grant will vest in full on the first to occur of (1) Issuer's 2023 Annual Meeting of Stockholders, or (2) the one-year anniversary of the date of grant. Settlement of this award has been deferred until the Reporting Person's separation from service with the Issuer's Board of Directors.

F2 · derivative.expiration_date: Award of RSUs pursuant to Issuer's Board of Director's compensation policies granted under Issuer's 2014 Equity Incentive Plan. The grant will vest in full on the first to occur of (1) Issuer's 2023 Annual Meeting of Stockholders, or (2) the one-year anniversary of the date of grant. Settlement of this award has been deferred until the Reporting Person's separation from service with the Issuer's Board of Directors.

SEC source: 0001209191-21-034542 · doc4.xml · derivative · entry 1

FRIEL ROBERT F · CIK 0001224110 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,702

Underlying: Common Stock · 2,702 shares

Expires not disclosed

F1 · security: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's common stock upon vesting.

F2 · derivative.exercise_date: Award of RSUs pursuant to Issuer's Board of Director's compensation policies granted under Issuer's 2014 Equity Incentive Plan. The grant will vest in full on the first to occur of (1) Issuer's 2022 Annual Meeting of Stockholders, or (2) the one-year anniversary of the date of grant. Settlement of this award has been deferred until the Reporting Person's separation from service with the Issuer's Board of Directors.

F2 · derivative.expiration_date: Award of RSUs pursuant to Issuer's Board of Director's compensation policies granted under Issuer's 2014 Equity Incentive Plan. The grant will vest in full on the first to occur of (1) Issuer's 2022 Annual Meeting of Stockholders, or (2) the one-year anniversary of the date of grant. Settlement of this award has been deferred until the Reporting Person's separation from service with the Issuer's Board of Directors.

SEC source: 0001209191-21-032327 · doc4.xml · nonDerivative · entry 1

FRIEL ROBERT F · CIK 0001224110 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 26,735

F1 · shares: Reflects the award of restricted stock units. The Reporting Person elected to defer the vesting of the RSU Award until January 1, 2026.

F2 · balance_after: Amount shown reflects additional shares acquired via a dividend reinvestment plan or DRIP.

SEC source: 0001562180-21-003313 · primarydocument.xml · nonDerivative · entry 1

FRIEL ROBERT F · CIK 0001224110 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,798.98

F1 · price: These shares of restricted stock units will vest in full on the first anniversary of the date of grant and will be distributable under the terms of the Deferred Compensation Plan for Outside Directors.

F2 · balance_after: Reflects additional shares purchased through dividend reinvestments based on most recent plan statement.

SEC source: 0001209191-20-033000 · doc4.xml · derivative · entry 1

FRIEL ROBERT F · CIK 0001224110 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,095

Underlying: Common Stock · 3,095 shares

Expires not disclosed

F1 · security: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's common stock upon vesting.

F2 · derivative.exercise_date: Award of RSUs pursuant to Issuer's Board of Director's compensation policies granted under Issuer's 2014 Equity Incentive Plan. The grant will vest in full on the first to occur of (1) Issuer's 2021 Annual Meeting of Stockholders, or (2) the one-year anniversary of the date of grant. Settlement of this award has been deferred until the Reporting Person's separation from service with the Issuer's Board of Directors.

F2 · derivative.expiration_date: Award of RSUs pursuant to Issuer's Board of Director's compensation policies granted under Issuer's 2014 Equity Incentive Plan. The grant will vest in full on the first to occur of (1) Issuer's 2021 Annual Meeting of Stockholders, or (2) the one-year anniversary of the date of grant. Settlement of this award has been deferred until the Reporting Person's separation from service with the Issuer's Board of Directors.

SEC source: 0001209191-20-029097 · doc4.xml · nonDerivative · entry 1

FRIEL ROBERT F · CIK 0001224110 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,596

F1 · shares: Reflects the award of restricted stock units. The Reporting Person elected to defer the vesting of the RSU Award until January 2026.

F2 · balance_after: Additional shares also accrued through a qualified DRIP.

SEC source: 0001562180-20-003460 · primarydocument.xml · nonDerivative · entry 1

FRIEL ROBERT F · CIK 0001224110 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,219.1984

F1 · price: These shares of restricted stock units will vest in full on the first anniversary of the date of grant and will be distributable under the terms of the Deferred Compensation Plan for Outside Directors.

F2 · balance_after: Reflects additional shares purchased through dividend reinvestments based on most recent plan statement.

SEC source: 0001562180-20-001421 · primarydocument.xml · nonDerivative · entry 1

FRIEL ROBERT F · CIK 0001224110 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 244

SEC source: 0001209191-19-030829 · doc4.xml · nonDerivative · entry 1

FRIEL ROBERT F · CIK 0001224110 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,718

F1 · shares: Reflects the award of restricted stock units, which are scheduled to vest on the business day prior to the Xylem Inc. 2020 annual shareholders' meeting.

F2 · balance_after: Additional shares also accrued through a qualified DRIP.

SEC source: 0001209191-19-029063 · doc4.xml · derivative · entry 1

FRIEL ROBERT F · CIK 0001224110 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,577

Underlying: Common Stock · 2,577 shares

Expires not disclosed

F1 · security: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's common stock upon vesting.

F2 · derivative.exercise_date: Award of RSUs pursuant to Issuer's Board of Director's compensation policies granted under Issuer's 2014 Equity Incentive Plan. The grant will vest in full on the first to occur of (1) Issuer's 2020 Annual Meeting of Stockholders, or (2) the one-year anniversary of the date of grant. Settlement of this award has been deferred until the Reporting Person's separation from service with the Issuer's Board of Directors.

F2 · derivative.expiration_date: Award of RSUs pursuant to Issuer's Board of Director's compensation policies granted under Issuer's 2014 Equity Incentive Plan. The grant will vest in full on the first to occur of (1) Issuer's 2020 Annual Meeting of Stockholders, or (2) the one-year anniversary of the date of grant. Settlement of this award has been deferred until the Reporting Person's separation from service with the Issuer's Board of Directors.

SEC source: 0000899243-19-003727 · doc4.xml · nonDerivative · entry 1

FRIEL ROBERT F · CIK 0001224110 · Director · Chairman and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 570,662

F1 · shares: These shares are being surrendered to satisfy a tax withholding obligation upon vesting of restricted stock originally granted on February 9, 2016, as required by the Reporting Person's Restricted Stock Agreement.

SEC source: 0000899243-19-002857 · doc4.xml · derivative · entry 2

FRIEL ROBERT F · CIK 0001224110 · Director · Chairman and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 62,059

Underlying: Common Stock · 62,059 shares

Expires 2026-02-05

F2 · derivative.exercise_date: This option is scheduled to vest in three equal annual installments beginning on the first anniversary of the date of grant.

SEC source: 0000899243-19-002857 · doc4.xml · nonDerivative · entry 1

FRIEL ROBERT F · CIK 0001224110 · Director · Chairman and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 587,551

F1 · shares: Shares are time-based restricted stock that are scheduled to fully vest on the third anniversary of the date of grant.

SEC source: 0000899243-18-025773 · doc4.xml · derivative · entry 4

FRIEL ROBERT F · CIK 0001224110 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 150,612 shares

Expires 2020-02-05

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: This option became exercisable in three equal annual installments beginning on February 5, 2014, which was the first anniversary of the date on which the option was granted.

SEC source: 0000899243-18-025773 · doc4.xml · nonDerivative · entry 3

FRIEL ROBERT F · CIK 0001224110 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 572,657

F1 · kind: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by Mr. Friel on August 31, 2018.

F3 · price: The price reported represents a weighted average sale price of shares sold in multiple transactions at prices ranging from $97.30 to $98.29. The Reporting Person hereby undertakes, upon request of the Staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, to provide full information regarding the number of shares sold at each separate price.

SEC source: 0000899243-18-025773 · doc4.xml · nonDerivative · entry 2

FRIEL ROBERT F · CIK 0001224110 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 618,972

F1 · kind: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by Mr. Friel on August 31, 2018.

F2 · price: The price reported represents a weighted average sale price of shares sold in multiple transactions at prices ranging from $96.30 to $97.29. The Reporting Person hereby undertakes, upon request of the Staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, to provide full information regarding the number of shares sold at each separate price.

SEC source: 0000899243-18-025773 · doc4.xml · nonDerivative · entry 1

FRIEL ROBERT F · CIK 0001224110 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 723,269

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000899243-18-021369 · doc4.xml · derivative · entry 6

FRIEL ROBERT F · CIK 0001224110 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 215,870 shares

Expires 2019-02-07

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: This option became exercisable in three equal annual installments beginning on February 7, 2013, which was the first anniversary of the date on which the option was granted.

SEC source: 0000899243-18-021369 · doc4.xml · nonDerivative · entry 4

FRIEL ROBERT F · CIK 0001224110 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 572,657

F1 · kind: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by Mr. Friel on February 1, 2018.

F2 · price: The price reported represents a weighted average sale price of shares sold in multiple transactions at prices ranging from $81.08 to $81.70. The Reporting Person hereby undertakes, upon request of the Staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, to provide full information regarding the number of shares sold at each separate price.

SEC source: 0000899243-18-021369 · doc4.xml · nonDerivative · entry 3

FRIEL ROBERT F · CIK 0001224110 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 788,527

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000899243-18-021369 · doc4.xml · derivative · entry 5

FRIEL ROBERT F · CIK 0001224110 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 215,870

Underlying: Common Stock · 2,709 shares

Expires 2019-02-07

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: This option became exercisable in three equal annual installments beginning on February 7, 2013, which was the first anniversary of the date on which the option was granted.

SEC source: 0000899243-18-021369 · doc4.xml · nonDerivative · entry 2

FRIEL ROBERT F · CIK 0001224110 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 572,657

F1 · kind: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by Mr. Friel on February 1, 2018.

SEC source: 0000899243-18-021369 · doc4.xml · nonDerivative · entry 1

FRIEL ROBERT F · CIK 0001224110 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 575,366

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-18-029116 · doc4.xml · nonDerivative · entry 1

FRIEL ROBERT F · CIK 0001224110 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,805

F1 · shares: Reflects the award of restricted stock units, which are scheduled to vest on the business day prior to the Xylem Inc. 2019 annual shareholders' meeting.

F2 · balance_after: Additional shares also accrued through a qualified DRIP.

SEC source: 0001209191-18-028416 · doc4.xml · derivative · entry 1

FRIEL ROBERT F · CIK 0001224110 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,230

Underlying: Common Stock · 3,230 shares

Expires not disclosed

F1 · security: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's common stock upon vesting.

F2 · derivative.exercise_date: Award of RSUs pursuant to Issuer's Board of Director's compensation policies granted under Issuer's 2014 Equity Incentive Plan. The grant will vest in full on the first to occur of (1) Issuer's 2019 Annual Meeting of Stockholders, or (2) the one-year anniversary of the date of grant. Settlement of this award has been deferred until the Reporting Person's separation from service with the Issuer's Board of Directors.

F2 · derivative.expiration_date: Award of RSUs pursuant to Issuer's Board of Director's compensation policies granted under Issuer's 2014 Equity Incentive Plan. The grant will vest in full on the first to occur of (1) Issuer's 2019 Annual Meeting of Stockholders, or (2) the one-year anniversary of the date of grant. Settlement of this award has been deferred until the Reporting Person's separation from service with the Issuer's Board of Directors.

SEC source: 0000899243-18-003088 · doc4.xml · nonDerivative · entry 1

FRIEL ROBERT F · CIK 0001224110 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 572,657

F1 · shares: These shares are being surrendered to satisfy a tax withholding obligation upon vesting of restricted stock originally granted on February 3, 2015, as required by the Reporting Person's Restricted Stock Agreement.

SEC source: 0000899243-18-002572 · doc4.xml · derivative · entry 2

FRIEL ROBERT F · CIK 0001224110 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 75,947

Underlying: Common Stock · 75,947 shares

Expires 2025-01-30

F2 · derivative.exercise_date: This option is scheduled to vest in three equal annual installments beginning on the first anniversary of the date of grant.

SEC source: 0000899243-18-002572 · doc4.xml · nonDerivative · entry 1

FRIEL ROBERT F · CIK 0001224110 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 589,031

F1 · shares: Shares are time-based restricted stock that are scheduled to fully vest on the third anniversary of the date of grant.

SEC source: 0001209191-17-034403 · doc4.xml · derivative · entry 1

FRIEL ROBERT F · CIK 0001224110 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,130

Underlying: Common Stock · 2,130 shares

Expires not disclosed

F1 · security: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's common stock upon vesting.

F2 · derivative.exercise_date: Award of RSUs pursuant to Issuer's Board of Director's compensation policies granted under Issuer's 2014 Equity Incentive Plan. The grant will vest in full on the first to occur of (1) Issuer's 2018 Annual Meeting of Stockholders, or (2) the one-year anniversary of the date of grant. Settlement of this award has been deferred until January 15, 2025.

F2 · derivative.expiration_date: Award of RSUs pursuant to Issuer's Board of Director's compensation policies granted under Issuer's 2014 Equity Incentive Plan. The grant will vest in full on the first to occur of (1) Issuer's 2018 Annual Meeting of Stockholders, or (2) the one-year anniversary of the date of grant. Settlement of this award has been deferred until January 15, 2025.